Business Context and Reporting Period
This Form 6-K filing by GSK plc (the "Company") reports a transaction in its own shares for the month of April 2026. The filing details a share repurchase executed on April 21, 2026, pursuant to a non-discretionary agreement with BNP Paribas SA, originally announced on February 17, 2026.
Key Financial Metrics
The filing focuses exclusively on capital structure and share repurchase activity. It does not contain revenue, profit, cash flow, margin, or debt metrics.
- Shares Purchased (April 21, 2026): 335,000 ordinary shares.
- Price Range: Lowest 2,074.00p; Highest 2,130.00p.
- Volume-Weighted Average Price (VWAP): 2,103.08p.
- Total Treasury Shares Held: 260,412,615 ordinary shares.
- Shares in Issue (excluding Treasury): 4,055,786,419 ordinary shares.
- Total Voting Rights: 4,055,786,419.
- Treasury Share Voting Percentage: 6.42%.
- Cumulative Purchases (since Feb 17, 2026): 20,521,521 ordinary shares.
Material Changes
Following the purchase on April 21, 2026, the Company's treasury share count increased to 260,412,615. Consequently, the percentage of voting rights attributable to treasury shares is now 6.42%. The number of ordinary shares in issue remains 4,055,786,419. The filing does not provide comparative financial data for prior periods as it is a transaction report rather than a financial statement.
Guidance, Outlook, and Risks
The filing confirms the repurchase is part of the Company's existing buyback programme. It includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ materially from projections due to risks and uncertainties. These factors are referenced as being described in the "Risk Factors" section of GSK's Annual Report on Form 20-F for 2025. No specific operational guidance or outlook is provided in this document.
Investor Verification Checklist
- Verify the total number of treasury shares held (260,412,615) against the latest Form 20-F or quarterly reports.
- Confirm the remaining capacity under the existing buyback programme announced on February 17, 2026.
- Review the "Risk Factors" in the 2025 Form 20-F for details on uncertainties affecting forward-looking statements.
- Check the denominator for shareholder notification thresholds under FCA Disclosure Guidance and Transparency Rules (4,055,786,419 voting rights).